Nektar Therapeutics (NKTR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.25B
Last updated: Nov 17, 2026 at 4:33 PM ET
Nektar Therapeutics (NKTR) Stock Chart
Nektar Therapeutics (NKTR) has a latest price of $35.91 on Nov 17, 2026, 67.1% below its 52-week high of $109.00. Its price fell 36.6% over the past 12 months. The month-end price fell 79.1% over the 10 years through Oct 2026, a compound annual decline of 14.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $1,593.10 in Mar 2018 and its lowest $7.03 in Oct 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NKTR with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NKTR.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 52.8%, and over 6 months it fell 46.9%. The month-end price rose 452.8% over the 3 years through Oct 2026, a compound annual rate of 76.8%.
| Period | Change |
|---|---|
| 1 month | -2.0% |
| 3 months | -52.8% |
| 6 months | -46.9% |
| 12 months | -36.6% |
| 12 months, with dividends | -36.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +452.8% | +76.8% |
| 5 years | -82.9% | -29.8% |
| 10 years | -79.1% | -14.5% |
Price by Year
Its best calendar year was 2017, when the price rose 386.7%, and its weakest was 2022, when it fell 83.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $38.87 | -8.1% |
| 2025 | $42.28 | +203.2% |
| 2024 | $13.94 | +64.6% |
| 2023 | $8.47 | -75.0% |
| 2022 | $33.88 | -83.3% |
| 2021 | $202.55 | -20.5% |
| 2020 | $254.87 | -21.3% |
| 2019 | $323.69 | -34.3% |
| 2018 | $492.80 | -45.0% |
| 2017 | $895.35 | +386.7% |
Trading Range
The price is 23.5% below its 50-day average of $46.93 and 44.8% below its 200-day average of $65.04.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $35.91 | |
| 52-week high | $109.00 | -67.1% |
| 52-week low | $33.40 | +7.5% |
| 50-day average | $46.93 | -23.5% |
| 200-day average | $65.04 | -44.8% |
Price Risk
Over 3 years, its largest fall from a peak was 73.2%.
| Measure | Value |
|---|---|
| 1-year beta | 1.06 |
| Largest fall, 1 year | -64.3% |
| Largest fall, 3 years | -73.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NKTR
What is NKTR's 1-year price change?
Nektar Therapeutics's price fell 36.6% over the past 12 months. With dividends included, the 12-month total return was -36.6%.
What is NKTR's 5-year price change?
Nektar Therapeutics's month-end price fell 82.9% over the 5 years through Oct 2026, a compound annual decline of 29.8%. These figures leave out dividends.
What is NKTR's 52-week high and low?
Nektar Therapeutics's 52-week high is $109.00 and its 52-week low is $33.40. Its latest price of $35.91 on Nov 17, 2026 is 67.1% below the high.
What is NKTR's beta?
Nektar Therapeutics's 1-year beta against the S&P 500 is 1.06, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 64.3%.
Is the NKTR chart free?
Yes. Advanced Charting for NKTR is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NKTR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors